134 related articles for article (PubMed ID: 19901093)
1. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Tarbet EB; Morrey JD; Furuta Y
Antimicrob Agents Chemother; 2010 Jan; 54(1):126-33. PubMed ID: 19901093
[TBL] [Abstract][Full Text] [Related]
2. Effects and mechanism of Qingke Pingchuan granules against influenza virus infection.
He L; Cao J; Xie X; Zhang Y; Zhang X; Wang H; Ma L
Arch Virol; 2024 May; 169(6):130. PubMed ID: 38807015
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Immune-Modulatory Activity of Lefamulin in an Influenza Virus A (H1N1) Infection Model in Mice.
Paukner S; Kimber S; Cumper C; Rea-Davies T; Sueiro Ballesteros L; Kirkham C; Hargreaves A; Gelone SP; Richards C; Wicha WW
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791439
[TBL] [Abstract][Full Text] [Related]
4. Impaired wound healing predisposes obese mice to severe influenza virus infection.
O'Brien KB; Vogel P; Duan S; Govorkova EA; Webby RJ; McCullers JA; Schultz-Cherry S
J Infect Dis; 2012 Jan; 205(2):252-61. PubMed ID: 22147799
[TBL] [Abstract][Full Text] [Related]
5. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia.
Tuvim MJ; Gilbert BE; Dickey BF; Evans SE
PLoS One; 2012; 7(1):e30596. PubMed ID: 22299046
[TBL] [Abstract][Full Text] [Related]
6. Insights into inflammation and influenza.
Simmons C; Farrar J
N Engl J Med; 2008 Oct; 359(15):1621-3. PubMed ID: 18843127
[No Abstract] [Full Text] [Related]
7. Postexposure Protective Efficacy of T-705 (Favipiravir) Against Sudan Virus Infection in Guinea Pigs.
Rahim MN; Zhang Z; He S; Zhu W; Banadyga L; Safronetz D; Qiu X
J Infect Dis; 2018 Nov; 218(suppl_5):S649-S657. PubMed ID: 29982696
[TBL] [Abstract][Full Text] [Related]
8. Modeling amantadine treatment of influenza A virus in vitro.
Beauchemin CA; McSharry JJ; Drusano GL; Nguyen JT; Went GT; Ribeiro RM; Perelson AS
J Theor Biol; 2008 Sep; 254(2):439-51. PubMed ID: 18653201
[TBL] [Abstract][Full Text] [Related]
9. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.
Wang Y; Zhong W; Salam A; Tarning J; Zhan Q; Huang JA; Weng H; Bai C; Ren Y; Yamada K; Wang D; Guo Q; Fang Q; Tsutomu S; Zou X; Li H; Gillesen A; Castle L; Chen C; Li H; Zhen J; Lu B; Duan J; Guo L; Jiang J; Cao R; Fan G; Li J; Hayden FG; Wang C; Horby P; Cao B
EBioMedicine; 2020 Dec; 62():103125. PubMed ID: 33232871
[TBL] [Abstract][Full Text] [Related]
10. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
Kiso M; Takahashi K; Sakai-Tagawa Y; Shinya K; Sakabe S; Le QM; Ozawa M; Furuta Y; Kawaoka Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):882-7. PubMed ID: 20080770
[TBL] [Abstract][Full Text] [Related]
11. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Furuta Y; Gowen BB; Takahashi K; Shiraki K; Smee DF; Barnard DL
Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.
Sangawa H; Komeno T; Nishikawa H; Yoshida A; Takahashi K; Nomura N; Furuta Y
Antimicrob Agents Chemother; 2013 Nov; 57(11):5202-8. PubMed ID: 23917318
[TBL] [Abstract][Full Text] [Related]
13. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.
Smee DF; Tarbet EB; Furuta Y; Morrey JD; Barnard DL
Future Virol; 2013 Nov; 8(11):1085-1094. PubMed ID: 24563658
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
15. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K; Mishin VP; Deyde VM; Furuta Y; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2010 Jun; 54(6):2517-24. PubMed ID: 20350949
[TBL] [Abstract][Full Text] [Related]
16. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Furuta Y; Komeno T; Nakamura T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(7):449-463. PubMed ID: 28769016
[TBL] [Abstract][Full Text] [Related]
17. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
Irie K; Nakagawa A; Fujita H; Tamura R; Eto M; Ikesue H; Muroi N; Tomii K; Hashida T
Clin Transl Sci; 2020 Sep; 13(5):880-885. PubMed ID: 32475019
[TBL] [Abstract][Full Text] [Related]
19. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.
Madelain V; Guedj J; Mentré F; Nguyen TH; Jacquot F; Oestereich L; Kadota T; Yamada K; Taburet AM; de Lamballerie X; Raoul H
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27736754
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
